Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)
Latest Information Update: 01 Mar 2025
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms EXCITE Trial; OU-SCC-EXCITE; OUSCCEXCITE; SCC-EXCITE
Most Recent Events
- 24 Feb 2025 Planned number of patients changed from 12 to 13.
- 24 Feb 2025 Planned End Date changed from 1 Nov 2024 to 1 Dec 2026.
- 24 Feb 2025 Planned primary completion date changed from 1 Nov 2024 to 1 Jun 2026.